knowcompoundsphylloquinone
Specimen compound organic compoundPlate I
Phylloquinone

- Formula
- C31H46O2
- Molar mass
- 450.707 g/mol
- ChEBI
- CHEBI:18067
- PubChem CID
- 5284607
- InChIKey
- MBWXNTAXLNYFJB-NKFFZRIASA-N
↓ lowered 2 findings in 2 endpoints · – no difference found 3 in 3
01 · the evidence, ordered
What the evidence says
- Strong
- 0
- Moderate
- 3
- Limited
- 0
- Very limited
- 2
- Insufficient
- 0
Phylloquinone
Most findings
- All-site cancer incidence×1
- Femoral neck bone mineral density×1
- HOMA-IR×1
- Lumbar spine bone mineral density×1
- Serum undercarboxylated osteocalcin concentration×1
5 reference statements, not drawn · 36 compounds on the outer ring, not drawn
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
- All-site cancer incidence
- Femoral neck bone mineral density
- Lumbar spine bone mineral density
- HOMA-IR
- Serum undercarboxylated osteocalcin concentration
02 · findings
What phylloquinone moved, and by how much
- HR hazard ratio. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
5 shown
- All-site cancer incidenceMoved: lowersEffect, as reportedHR0.25[0.07 to 0.89]Evidence: ModeratePaper: PMID 189220412008
- Who
- Postmenopausal women with osteopenia, vitamin D replete, receiving calcium and vitamin D in both arms; follow-up up to 4 years
- Dose studied
- 5 mg vitamin K1 daily
Cancer incidence was lower in the vitamin K group than in the placebo group (three versus 12, p = 0.02; HR = 0.25, 95% CI 0.07 to 0.89).”
Quoted verbatim from Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial.RCTPermalink - Femoral neck bone mineral densityMoved: no difference foundEvidence: ModeratePaper: PMID 373386082023
- Who
- Post-menopausal women with osteoporosis and serum vitamin K1 of 0.4 µg/L or less, all on oral bisphosphonate with calcium and/or vitamin D; vitamin K1 arm against placebo, 18 months
- Dose studied
- 1 mg/day vitamin K1
Changes in BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP did not differ significantly following either K1 or MK-4 supplementation compared to placebo.”
Quoted verbatim from The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.RCTPermalink - Lumbar spine bone mineral densityMoved: no difference foundEvidence: ModeratePaper: PMID 373386082023
- Who
- Post-menopausal women with osteoporosis and serum vitamin K1 of 0.4 µg/L or less, all on oral bisphosphonate with calcium and/or vitamin D; vitamin K1 arm against placebo, 18 months
- Dose studied
- 1 mg/day vitamin K1
Changes in BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP did not differ significantly following either K1 or MK-4 supplementation compared to placebo.”
Quoted verbatim from The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.RCTPermalink - HOMA-IRMoved: no difference foundEvidence: Very limitedPaper: PMID 208810722010
- Who
- Community-dwelling postmenopausal women, 21 per arm; value at 12 months · n = 42
- Dose studied
- 1 mg phylloquinone daily for 12 months
Despite a decrease of ≈200% in ucOC concentrations, HOMA-IR was similar in the 2 groups at 6 and 12 mo (at 6 mo, HOMA-IR was 2.24 ± 0.54 and 1.52 ± 0.23 in the experimental and control groups, respectively; at 12 mo, HOMA-IR was 2.13 ± 0.38 and 1.47 ± 0.22 in the experimental and control groups, respectively; P = NS).”
Quoted verbatim from Effect of phylloquinone supplementation on glucose homeostasis in humans.RCT · 12 monthsPermalink - Serum undercarboxylated osteocalcin concentrationMoved: lowersEvidence: Very limitedPaper: PMID 172987082007
- Who
- Postmenopausal women in a 3 x 6-week randomised cross-over study; all periods included 10 microg vitamin D3/d; dose-dependent across placebo, 200 and 500 microg/d
- Dose studied
- 0 (placebo), 200 and 500 microg phylloquinone/d, 6 weeks each
With increasing phylloquinone intake, the concentration of serum gamma-carboxylated and under-gamma-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P < 0.001).”
Quoted verbatim from Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women.crossover · 6 weeksPermalink
No row matches these filters.
No dose is advised.
- HR hazard ratio. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
03 · identity
Structure
- Charge
- 0
- SMILES
- CC1=C(C/C=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=O)c2ccccc2C1=O
04 · figures · 1 plate
Plates

fig. 5Phylloquinone · MS2 [M+NH4]+ LC-ESI-QTOF positive · MassBank MSBNK-Antwerp_Univ-METOX_N108523_D7C8 (da Silva KM, CC BY)
05 · reach
What it touches on the way
What the reference databases state
5Reference statements
What the reference databases state
Evidence keyStatements
5 statements
- phylloquinone is metabolised by CYP4F11ProteinRhea RHEA:41516Inferred only
- phylloquinone is metabolised by CYP4F2ProteinRhea RHEA:41516Inferred only
- phylloquinone is a substrate of AIFM2ProteinRhea RHEA:74075Inferred only
- phylloquinone is a substrate of VKORC1ProteinRhea RHEA:57744Inferred only
- phylloquinone is a substrate of VKORC1L1ProteinRhea RHEA:57744Inferred only
6Reactions
07 · on the label · 2,523 products
Labelled products
Source: NIH DSLD · Ingredient: phylloquinone · 2,523 products · Declared amount per serving (the first 1,000 shown): 3.3–80,000 µg
979 labels of the first 1,000 shown state an amount21 do not
- 1st PhormM-Factor HeroVitamin K, as Phylloquinone80 µgper 3 capsulesDSLD:12881
- 1st PhormPrenatal PlusPhytonadione60 µgper 3 vegan capsulesDSLD:242935
- 21st CenturyDiabetic Support FormulaPhytonadione10 µgper 3 tabletsDSLD:11189
- 21st CenturyMega Multi for MenVitamin K, as Phytonadione75 µgper 2 tabletsDSLD:258471
- 21st CenturyMega Multi for WomenVitamin K, as Phytonadione75 µgper 2 tabletsDSLD:258472
- 21st CenturyOne Daily ActivePhytonadione25 µgper 1 tabletDSLD:11548
- 21st CenturyOne Daily Adults 50+Phytonadione20 µgper 1 tabletDSLD:11549
- 21st CenturyOne Daily EnergyPhytonadione25 µgper 1 tabletDSLD:11552
- 21st CenturyOne Daily EnergyVitamin K, as Phytonadione25 µgper 1 tabletDSLD:258482
- 21st CenturyOne Daily MaximumPhytonadione25 µgper 1 tabletDSLD:11558
- 21st CenturyOne Daily Men's HealthPhytonadione20 µgper 1 tabletDSLD:11559
- 21st CenturyOne Daily Weight ControlPhytonadione80 µgper 1 tabletDSLD:11560
Show the remaining 2,511Show the first 12
Label record: NIH Office of Dietary Supplements · CC0
08 · the record
Sources
1,097
papers screened for phylloquinone
- admitted
- 4
- read and discarded
- 1,022
- not read yet
- 71
Sources cited
4 papers · 5 findings